Delta‐Like Homolog 2 Facilitates Malignancy of Hepatocellular Carcinoma via Activating EGFR/PKM2 Signaling Pathway

Xiangye Liu,Tingting Li,Yuting Wang,Xiaoge Gao,Feitong Wang,Yang Chen,Kaisheng Wang,Weiming Luo,Fanyun Kong,Yanbo Kou,Hongjuan You,Delong Kong,Qing Zhang,Renxian Tang
DOI: https://doi.org/10.1002/mc.23836
2024-10-29
Molecular Carcinogenesis
Abstract:Delta‐like homolog 2 (DLK2) plays a crucial role in adipogenesis, chondrogenic differentiation, and the progression of certain cancers. However, the key roles of DLK2 underlying the progression of hepatocellular carcinoma (HCC) remain ambiguous. In the current study, we demonstrate that DLK2 is upregulated in HCC, significantly correlated with clinicopathological variables and serves as an independent diagnostic marker. Functional assays reveal that DLK2 facilitates malignant progression of HCC in vitro and in vivo models. Mechanistically, DLK2 binds to EGFR resulting in its auto‐phosphorylation, which activates NK‐κB pathway leading to P65‐dependent transcriptional upregulation of PKM2. Furthermore, that elevates both enzyme‐dependent and ‐independent activities of PKM2 contributing to cancer proliferation and metastasis. In summary, our findings demonstrate a novel pro‐tumoral role and mechanism of DLK2 in the regulation of HCC malignant progression, suggesting its potential as a clinical diagnostic marker and therapeutic target.
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?